1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. California >
  6. PAVmed Acquires Oncodisc

M&A Deal Summary

PAVmed Acquires Oncodisc

On June 2, 2021, PAVmed acquired medical products company Oncodisc

Acquisition Highlights
  • This is PAVmed’s 1st transaction in the Medical Products sector.
  • This is PAVmed’s 1st transaction in the United States.
  • This is PAVmed’s 1st transaction in California.

M&A Deal Summary
Date 2021-06-02
Target Oncodisc
Sector Medical Products
Buyer(s) PAVmed
Deal Type Add-on Acquisition
Advisor(s) Alwaysraise (Financial)

Target

Oncodisc

Walnut Creek, California, United States
Oncodisc is developing data-driven remote care technology. Oncodisc was founded in 2018 by physicians James Mitchell, M.D. and Andrew Thoreson, M.D. Oncodisc technology is designed to benefit cancer and chronic disease patients by providing artificial intelligence-embedded, physician-designed software integrated with intelligent vascular access technology. Its mission is to personalize care through remote detection of changes in patient health status and enhance doctor-patient communication.

Search 215,130 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

PAVmed

New York, New York, United States
Category Company
Founded 2014
Sector Medical Products
Employees39
Revenue 3M USD (2024)
DESCRIPTION

PAVmed is a multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. PAVmed was founded in 2014 and is based in New York, New York.

DEAL STATS #
Overall 1 of 2
Sector: Medical Products M&A 1 of 2
Type: Add-on Acquisition M&A Deals 1 of 2
State: California M&A 1 of 1
Country: United States M&A 1 of 2
Year: 2021 M&A 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-10-07 CapNostics

Concord, North Carolina, United States

CapNostics is a manufactures EsophaCap®—a U.S. FDA 510(k)-cleared and European CE Mark certified, non-endoscopic esophageal cell collection device which has been used in pre-commercial clinical research of esophageal precancer biomarkers at major academic medical centers. CapNostics is based in Concord, North Carolina.

Buy -
Mergr

Solution for

Product

Company

Legal